Evidence map›Paper›PMID 17400933›Full record

ReviewTobacco control2007

Asian herbal-tobacco cigarettes: "not medicine but less harmful"?

Aiyin Chen, Stanton Glantz, Elisa Tong

Abstract readReview
In one paragraph

Review in Tobacco control, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Chinese "herbal" cigarettes are as carcinogenic and addictive as regular cigarettes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aiyin ChenCentre for Tobacco Control Research and Education, University of California, San Francisco, San Francisco, California, USA.
Stanton Glantz
Elisa Tong

Funding

ANALYSIS OF TOBACCO INDUSTRY DOCUMENTSR01CA087472 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LING, PAMELA MAY · 2000 to 2018
$12.5M
Tobacco Control Policy Analysis & Intervention Evaluation in China and IndonesiaR01TW005938 · FIC · UNIVERSITY OF CALIFORNIA BERKELEY · PI HU, TEH-WEI · 2002 to 2011
$3.6M
FIC NIH HHS R01 TW005938FIC NIH HHS TW05938NCI NIH HHS CA-87472
6 · The paper itself

Abstract

objectiveTo describe the development and health claims of Asian herbal-tobacco cigarettes.

methodsAnalysis of international news sources, company websites, and the transnational tobacco companies' (TTC) documents. PubMed searches of herbs and brands.

resultsTwenty-three brands were identified, mainly from China. Many products claimed to relieve respiratory symptoms and reduce toxins, with four herb-only products advertised for smoking cessation. No literature was found to verify the health claims, except one Korean trial of an herb-only product. Asian herbal-tobacco cigarettes were initially produced by China by the 1970s and introduced to Japan in the 1980s. Despite initial news about research demonstrating a safer cigarette, the TTC analyses of these cigarettes suggest that these early products were not palatable and had potentially toxic cardiovascular effects. By the late 1990s, China began producing more herbal-tobacco cigarettes in a renewed effort to reduce harmful constituents in cigarettes. After 2000, tobacco companies from Korea, Taiwan, and Thailand began producing similar products. Tobacco control groups in Japan, Taiwan, and Thailand voiced concern over the health claims of herbal-tobacco products. In 2005, China designated two herbal-tobacco brands as key for development.

conclusionAsian herbal-tobacco cigarettes claim to reduce harm, but no published literature is available to verify these claims or investigate unidentified toxicities. The increase in Asian herbal-tobacco cigarette production by 2000 coincides with the Asian tobacco companies' regular scientific meetings with TTCs and their interest in harm reduction. Asia faces additional challenges in tobacco control with these culturally concordant products that may discourage smokers from quitting.

Indexed as

Harm ReductionPlants, MedicinalSmokingAsiaChinaHumansTobacco Industry

Identifiers

PMID17400933
PMCPMC2598477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.